Table 2. Overview of reviews.
| Review characteristics (N = 52) |
Count (%) | |
|---|---|---|
| Review type | Narrative synthesis | 18 (35%) |
| Meta-analysis | 24 (46%) | |
| Scoping review | 3 (6%) | |
| Systematic overview (including specific section on fatigue interventions) | 4 (7%) | |
| Conference proceedings—abstract | 3 (6%) | |
| Year of publication | No date | 2 (4%) |
| Pre-2005 | 2 (4%) | |
| 2006–2011 | 15 (29%) | |
| 2012–2015 | 23 (44%) | |
| 2016 | 8 (15%) | |
| 2017 | 2 (4%) | |
| Health condition studied | Multiple Sclerosis | 18 (34%) |
| Chronic Fatigue Syndrome | 8 (15%) | |
| ‘Mixed’ clinical populations | 6 (11%) | |
| Parkinson’s Disease | 3 (6%) | |
| Systemic Lupus Erythematosus | 3 (6%) | |
| Rheumatoid Arthritis | 3 (6%) | |
| End Stage Kidney Disease | 2 (4%) | |
| Inflammatory Bowel Disease | 1 (2%) | |
| Sarcoidosis | 1 (2%) | |
| Traumatic Brain Injury | 1 (2%) | |
| HIV | 1 (2%) | |
| Heart disease | 1 (2%) | |
| Fibromyalgia | 1 (2%) | |
| Sjogren’s Syndrome | 1 (2%) | |
| Peripheral neuropathy | 1 (2%) | |
| Post-stroke | 1 (2%) | |
| Review focus | Pharmacological interventions Non-pharmacological interventions Mixture/not specified |
10 (19%) 28 (54%) 14 (27%) |
| Review size | Number of studies included in reviews - Minimum to maximum - Average |
0–45 17 |